Hee Jeong Kim1, Beom Seok Koh1, Jong Han Yu1, Jong Won Lee1, Byung Ho Son1, Sung Bae Kim2, Sei Hyun Ahn3. 1. Department of Surgery, College of Medicine, University of Ulsan and Asan Medical Center, Republic of Korea. 2. Department of Oncology, College of Medicine, University of Ulsan and Asan Medical Center, Republic of Korea. 3. Department of Surgery, College of Medicine, University of Ulsan and Asan Medical Center, Republic of Korea. Electronic address: ahnsh@amc.seoul.kr.
Abstract
BACKGROUND: We investigated the effect of breast cancer adjuvant treatment on vitamin D status, as measured by serum hydroxyvitamin D (25OHD). METHODS: Premenopausal patients (n=483) diagnosed with non-metastatic breast cancer in 2009 at Asan Medical Center had serum 25OHD levels prospectively analysed at diagnosis and 6 and 12months after surgery. We excluded patients who took vitamin D supplements or received neoadjuvant chemotherapy. Vitamin D sufficiency was defined as a serum level of ⩾30ng/ml, insufficiency as 20-29ng/ml and deficiency as <20ng/ml. RESULTS: Compared with baseline serum 25OHD, patients who received chemotherapy had decreased serum 25OHD levels at 6months (-5.52ng/ml, p=0.003) and 12months (-1.24ng/ml, p=0.517) and patients who received anti-hormone therapy had significantly increased serum 25OHD levels at 6months (+3.00ng/ml, p=0.681) and 12months (+6.47ng/ml, p=0.002, respectively). Among patients who received chemotherapy, 49.5% were vitamin D sufficient at diagnosis but only 26.9% were sufficient 6months after finishing chemotherapy and this percentage increased to 45.2% at 12months. CONCLUSIONS: Vitamin D levels decrease during chemotherapy but recover after treatment ends. Anti-hormone therapy with tamoxifen causes serum vitamin D levels to increase. Whether the increased serum vitamin D affects the antitumour effect of the tamoxifen has yet to be determined.
BACKGROUND: We investigated the effect of breast cancer adjuvant treatment on vitamin D status, as measured by serum hydroxyvitamin D (25OHD). METHODS: Premenopausal patients (n=483) diagnosed with non-metastatic breast cancer in 2009 at Asan Medical Center had serum 25OHD levels prospectively analysed at diagnosis and 6 and 12months after surgery. We excluded patients who took vitamin D supplements or received neoadjuvant chemotherapy. Vitamin D sufficiency was defined as a serum level of ⩾30ng/ml, insufficiency as 20-29ng/ml and deficiency as <20ng/ml. RESULTS: Compared with baseline serum 25OHD, patients who received chemotherapy had decreased serum 25OHD levels at 6months (-5.52ng/ml, p=0.003) and 12months (-1.24ng/ml, p=0.517) and patients who received anti-hormone therapy had significantly increased serum 25OHD levels at 6months (+3.00ng/ml, p=0.681) and 12months (+6.47ng/ml, p=0.002, respectively). Among patients who received chemotherapy, 49.5% were vitamin D sufficient at diagnosis but only 26.9% were sufficient 6months after finishing chemotherapy and this percentage increased to 45.2% at 12months. CONCLUSIONS:Vitamin D levels decrease during chemotherapy but recover after treatment ends. Anti-hormone therapy with tamoxifen causes serum vitamin D levels to increase. Whether the increased serum vitamin D affects the antitumour effect of the tamoxifen has yet to be determined.
Authors: Song Yao; Marilyn L Kwan; Isaac J Ergas; Janise M Roh; Ting-Yuan David Cheng; Chi-Chen Hong; Susan E McCann; Li Tang; Warren Davis; Song Liu; Charles P Quesenberry; Marion M Lee; Christine B Ambrosone; Lawrence H Kushi Journal: JAMA Oncol Date: 2017-03-01 Impact factor: 31.777
Authors: Ji Su Kim; Caspar Christian Haule; Joo Heung Kim; Sung Mook Lim; Kwang Hyun Yoon; Jee Ye Kim; Hyung Seok Park; Seho Park; Seung Il Kim; Young Up Cho; Byeong-Woo Park Journal: J Breast Cancer Date: 2018-06-20 Impact factor: 3.588